Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

The rate of antipsychotic drug use in nursing homes has remained stubbornly high. Experts are concerned about misuse.

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

An estimated one to three million people visit the emergency room with a concussion in the U.S. each year, according to the ...

Roche narrows pipeline to focus more on weight-loss franchise, following setbacks in Alzheimer's and lung cancer ...

Eli Lilly’s Alzheimer’s drug, Kisunla, has received approval from the Japanese Ministry of Health, Labour and Welfare. This ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Researchers are finding new ways to help people to detect Alzheimer’s in the early stages that makes life with the disease more livable.

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with ...